Italia markets open in 4 hours 21 minutes

uniQure N.V. (0EE0.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
4,6400+0,0900 (+1,98%)
Alla chiusura: 07:00PM BST
Schermo intero
Chiusura precedente4,5500
Aperto0,0000
Denaro0,0000 x 0
Lettera0,0000 x 0
Min-Max giorno0,0000 - 0,0000
Intervallo di 52 settimane
Volume70
Media Volume2.359
Capitalizzazione1,779M
Beta (5 anni mensile)0,95
Rapporto PE (ttm)0,01
EPS (ttm)6,8870
Prossima data utili07 mag 2024 - 13 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs

    ~ Reduction of 28% of workforce not related to HEMGENIX® manufacturing obligations; Total cost savings of $180 million to extend cash runway into second quarter of 2027 ~ ~ Discontinuing investments in more than half of research and technology projects, centralizing operations, and streamlining organization ~ ~ Prioritizing continued development of AMT-130 in Huntington’s disease and near-term initiation of clinical trials for AMT-260 in refractory mesial temporal lobe epilepsy, AMT-162 in SOD1-

  • GlobeNewswire

    uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    LEXINGTON, Mass. and AMSTERDAM, Oct. 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the grant of inducement equity awards to newly hired employees. The Company granted equity awards to 42 employees as a material inducement to commencing their employment. In the aggregate, those employees received 98,900 restricted share units and options to purchase 90,500 ordinary

  • GlobeNewswire

    uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy

    Clinical trial initiation expected in the fourth quarter of 2023LEXINGTON, Mass. and AMSTERDAM, Sept. 05, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for AMT-260, the Company’s gene therapy candidate for refractory mesial temporal lobe epilepsy (MTLE). AMT-260